Principal Investigators

    Professor AH Schapira

    Institution

    University College London

    Contact information of lead PI

    Country

    United Kingdom

    Title of project or programme

    Targeting glucocerebrosidase for disease-modifying treatments in Parkinson's disease

    Source of funding information

    MRC

    Total sum awarded (Euro)

    € 290,391

    Start date of award

    24/02/2014

    Total duration of award in years

    2

    Keywords

    Research Abstract

    Parkinson disease is a progressive neurodegenerative disorder treatment for which is limited to improving symptoms and there is an urgent need to develop drugs that slow progression. It has recently been shown that mutations of the glucocerebrosidase gene result in a very significant increased risk for PD, and that approximately 10% of patients carry such mutations. Our project is designed to explore the mechanisms by which the mutations increase the risk for PD and to test candidate drugs that reverse the biochemical changes induced by the mutations. We hypothesise that this will result in a reduction in alpha-synuclein levels, the protein that builds up in Parkinson neurons and that is thought to be at the centre of the degenerative process. The candidate drugs will first be tested in cell and animal models of the mutations as part of this international collaboration in confirming this proof of principle. Positive results will lead to drug development for patients.

    Further information available at:

Types: Investments < €500k
Member States: United Kingdom
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF